Special notice
Post-Market Bioequivalence (BE) Studies
Food and Drug Administration, FDA Office of Acq Grant SVCS. Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
Response deadline
November 21, 2025 at 2:20 PM EST
Closed 345 days ago. Posted November 21, 2025. Scheduled to archive November 21, 2025.
Get the next one like this from Food and Drug Administration by email, the day it is posted.Find my opportunities
This one closed in 2025
127 like it are open now in research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology)
- SBIR FY26 Phase I Broad Agency Announcement
Environmental Protection Agency, Water, Tribal & Science Division
SolicitationSmall businessNAICS 541715Anywhere in the US68HERW26R0102Closes in 8 daysNov 9 - System of systems Technology Integration Tool Chain for Heterogeneous Electronic Systems (STITCHES) Sources Sought
Department of the Air Force, FA2057 AFLCMC HNJK
Sources soughtNAICS 541715Location not publishedSTITCHES_001Closes in 13 daysNov 14 - Synthesis and Distribution of Drugs of Abuse and Related Compounds
National Institutes of Health, National Institutes of Health Nida
Sources soughtNAICS 541715Anywhere in the US75N98027R00006OTCloses in 19 daysNov 20
Description
As published on SAM.gov.
This notication serves as a cancellation of a requirement in name FDAFO121683-Post-Market Bioequivalence (BE) Studies
Attachments
Files listed on SAM.gov. The ones we hold a copy of download from here; the rest open SAM's download, which needs no account.
- SAM-Cancellation Notice.pdf147 KB, November 21, 2025
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
November 21, 2025
Special notice, originally solicitation
Due November 21, 2025 at 2:20 PM EST. SAM.gov, notice 1303d7fd61d7428e8949ce0ba34b8f5b
2 revisions on SAM
- November 21, 2025: publish, special notice
- August 19, 2025: publish, solicitation
Points of contact
- Telisha Wilsontelisha.wilson@fda.hhs.gov2404027572